Search Results for: The Human Vaccines Project Boehringer
Articles
November 21, 2016
The Human Vaccines Project & Boehringer Ingelheim Partner to Accelerate the Development of Cancer Vaccines & Immunotherapies November 21, 2016
The Human Vaccines Project and Boehringer Ingelheim are pleased to announce a 3-year collaboration agreement to support their mutual objective...
January 4, 2024
Boehringer Ingelheim Licenses Multiple Dark Antigens From Enara Bio to Develop Off-the-Shelf Immunotherapies for Non-Small Cell Lung Cancer January 4, 2024
Enara Bio recently announced Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated...
May 19, 2020
CureVac´s Optimized mRNA Platform Provides Positive PreClinical Results at Low Dose for COVID-19 Vaccine Candidate May 19, 2020
CureVac AG recently announced positive preclinical results at a low dose for its lead vaccine candidate against the novel Coronavirus...
April 30, 2013
FORMULATION DEVELOPMENT - Trends & Opportunities in Particle Design Technologies - Life Sciences & Biopharma in the Spotlight April 30, 2013
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical industry.
